KUALA LUMPUR (Aug 13): Pharmaniaga Bhd (KL:PHARMA) posted a more than three fold jump in net profit for the second quarter ended June 30, 2026 thanks to interest savings from partial repayment of borrowings and effective inventory management.

The company reported a net profit of RM12.49 million compared with RM3.96 million the year before.  The company saved some RM7 million in interest during the quarter.

This was on 12% higher revenue of RM1.04 billion, compared with RM926.86 million the year before on higher volume orders from government hospitals and sales from the private segment.

The company declared a second interim dividend of 0.48 sen for the quarter with ex-date on Sep 14 and payment date on Oct 13.

The company expects to see contribution from its first human insulin supply contract valued at RM281.7 million from the second half of 2026. 

It is focusing on accelerating the commercialisation of its biopharmaceutical portfolio while strengthening its pharmaceutical and logistics business and expanding its regional footprint.

"Looking ahead, we remain encouraged by the steady progress of our pharmaceutical and biopharmaceutical initiatives, particularly the localisation of strategic healthcare products that will strengthen Malaysia's supply security while supporting long-term margin enhancement,” Pharmaniaga managing director, Datuk Zulkifli Jafar said in a statement.  

“During the quarter, our vaccine localisation programme has marked significant milestones that brings us closer to commercialisation. We successfully completed the process validation batches for our Pneumococcal Conjugate Vaccine (PCV-13), while our manufacturing facilities underwent inspection by the National Pharmaceutical Regulatory Agency (NPRA) and were certified as compliant with Good Manufacturing Practice (GMP) requirements.”

He added that together with its growing product pipeline and the RM281.7 million three-year human insulin supply contract, Pharmaniaga said these developments support its long-term growth prospects. 

Net profit for the six month period was 31% higher at RM43.96 million, compared with RM33.54 million.

Revenue was almost 12% higher at RM2.22 billion compared with RM1.98 billion.

Pharmaniaga’s shares were down a sen or 0.85% to RM1.17 a share on Thursday, valuing the company at RM1.53 billion.